Corrigendum to "A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)": [ESMO Open 9 (2024) 103668]
对“tepotinib治疗携带MET外显子14跳跃突变或扩增的晚期实体瘤患者的II期研究(KCSG AL19-17)”的更正:[ESMO Open 9 (2024) 103668]
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.104302
Kang, E J; Yang, Y; Lee, S; Kim, Y J; Lim, S M; Ahn, M-J; Choi, Y J; Lee, Y; Kim, T M; Kim, I; Ahn, H K; Jeung, H-C; Lee, S I; Oh, S Y; Bae, W K; Ryu, H; Park, K H; Lee, K H